Table of Content

25 August 2021, Volume 13 Issue 4 Previous Issue    Next Issue

Select

Expert consensus on clinical detection and application of homologous recombination deficiency, 2021 Genetic Tumor Markers Collaboration Group, Tumor Biomarker Committee, China Anti⁃cancer Association, 2021, 13 (4):  329-338.  doi: 10.3969/j.issn.1674-5671.2021.04.01 Abstract ( 4799 )   PDF (548KB) ( 1912 )   Save Related Articles | Metrics

Select

Thinking and exploration of cancer prevention and control strategies under the background of healthy China strategy GUO Xiaofei, YU Da 2021, 13 (4):  339-343.  doi: 10.3969/j.issn.1674-5671.2021.04.02 Abstract ( 305 )   PDF (498KB) ( 380 )   Save Related Articles | Metrics

Select

Research progress of BCL⁃2 inhibitors in hematological malignancies WANG Henan, WANG Liang 2021, 13 (4):  344-351.  doi: 10.3969/j.issn.1674-5671.2021.04.03 Abstract ( 371 )   PDF (570KB) ( 404 )   Save Related Articles | Metrics

Select

Research progress of molecular genetics of T⁃cell acute lymphoblastic leukemia/lymphoma ZHANG Xiaoting, DENG Lan, HUANG Rui 2021, 13 (4):  352-358.  doi: 10.3969/j.issn.1674-5671.2021.04.04 Abstract ( 291 )   PDF (493KB) ( 512 )   Save Related Articles | Metrics

Select

Efficacy of PD⁃1 inhibitors in the maintenance treatment for diffuse large B⁃cell lymphoma: A single⁃center retrospective case⁃control study LIU Xuanyong, GUO Zhi, XIE Jing, CHEN Lina, WANG Yueqiao, ZHANG Yi⁃huizhi, CHEN Xiao, LI Xumian, WEI Liya, 2021, 13 (4):  359-364.  doi: 10.3969/j.issn.1674-5671.2021.04.05 Abstract ( 311 )   PDF (607KB) ( 267 )   Save Objective To investigate the impact of PD-1 inhibitors maintenance therapy on prognosis of diffuse large B-cell lymphoma(DLBCL) patients. Methods The DLBCL patients who achieved complete response(CR) after induction chemotherapy admitted to our center from March 2018 to March 2019 were retrospectively analyzed. Among them, the therapy group received PD-1 inhibitors maintenance therapy(30 cases), and 30 patients who did not receive maintenance therapy during the same period were selected as the control group. The relapse-free survival(RFS) rate of the two groups were compared, and the efficacy and safety of PD-1 inhibitors maintenance therapy were observed. Results Follow-up until March 2021, the 2-year RFS rates of the therapy group and the control group were 80.0% and 73.3%(P=0.542), respectively. Subgroup analysis showed that the patients with international prognostic index(IPI) score ≥ 3points (70% vs 22.2%, P=0.037), non-GCB type(90.9% vs 45.5%, P=0.022) received PD-1 inhibitors maintenance treatment had a significant benefit in 2-year RFS rates compared with the control group. The main adverse reactions in the therapy group were controllable, all of grade Ⅰ-Ⅱ, including rash(2 cases), leukopenia(5 cases), hypothyroidism(3 cases) , liver damage(1 cases), thrombocytopenia(1 cases), abnormal glucose and lipid metabolism(1 cases) , digestive tract reaction(1 cases). Conclusions The maintenance treatment with PD-1 inhibitors cannot significantly improve the RFS of patients with DLBCL, but it has a potential advantages in patients with IPI score ≥ 3points and non-GCB DLBCL. Related Articles | Metrics

Select

Prognosis of cancer⁃related sepsis in adult intensive care unit: A 5⁃year single center retrospective cohort study ZHAO Lei, CHEN Wei, ZHEN Jie, GU Hongyan, ZANG Xuefeng, LU Feiping, LIU Yang 2021, 13 (4):  365-369.  doi: 10.3969/j.issn.1674-5671.2021.04.06 Abstract ( 244 )   PDF (485KB) ( 131 )   Save Objective To analyze the prognosis of cancer-related sepsis in adult intensive care unit (ICU) to provide the evidence for clinical treatment. Methods The medical records of 1, 325 adult septic patients in ICU, collected from the scientific research data system of Beijing Shijitan Hospital, Capital Medical University between January 2016 and December 2020, were analyzed retrospectively. The patients were divided into the cancer-related sepsis group and the non-cancer-related sepsis group according to whether the patient had tumor diseases. The acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ) score, infection site, number and time of mechanical ventilation, time of continuous renal replacement therapy (CRRT), proportion of organ failure, survival rate and length of hospital stay were compared between the two groups. Results Among the 1, 325 adult sepsis patients, 493 cases were cancer-related sepsis and 832 cases were non-cancer-related sepsis. APACHE Ⅱ score of cancer-related sepsis group was higher than that of non-cancer-related sepsis (P=0.001). There were significant differences in infection sites between the two groups when admitted to ICU, mainly manifested as lower proportion of respiratory tract infection in patients with cancer-related sepsis group and higher proportion of infection in digestive tract, urinary tract, blood, central nerve, skin soft tissue and other parts (all P <0.001). The number and time of patients receiving mechanical ventilation and CRRT, the proportion of fungal infection and unidentified pathogens in cancer-related sepsis group were also higher than those in non-cancer-related sepsis group (all P<0.05). The proportion of respiratory failure in cancer-related sepsis group was lower than that in non-cancer-related sepsis group, while the proportion of shock, heart failure, renal insufficiency, liver insufficiency, gastrointestinal dysfunction and coagulation dysfunction was higher than that in non-cancer-related sepsis group(all P<0.05). The 28 days survival rate and ICU overall survival rate of patients with non-cancer-related sepsis were significantly better than those with cancer-related sepsis (all P<0.05). Conclusions Patients with cancer-related sepsis are more severely ill when admitted to ICU, and the organ dysfunction, life support methods and pathogens are all different from those of patients with non-cancer-related sepsis, and the survival rate is also lower. Therefore, it is necessary to study the evaluation, diagnosis and treatment strategies of cancer-related sepsis. Related Articles | Metrics

Select

Establishment and analysis of therapeutic efficacy prediction model of ruxolitinib in patients with myelofibrosis ZHANG Xuejiao, WANG Yue, TAN Yunshan, LIU Peng 2021, 13 (4):  370-375.  doi: 10.3969/j.issn.1674-5671.2021.04.07 Abstract ( 311 )   PDF (525KB) ( 180 )   Save Objective To investigate the efficacy of Ruxolitinib in the treatment of myelofibrosis and its predictive indices. Methods A total of 64 patients with myelofibrosis, treated with Ruxolitinib in the Department of Hematology, Zhongshan Hospital, Fudan University from November 2017 to December 2020, were collected as the study subjects. The endpoint was the reduction of spleen volume ≥35% from baseline at 12 weeks of treatment. LASSO regression was used to screen the predictive indices of the therapeutic effect of Ruxolitinib in the treatment of myelofibrosis. The regression model was established by the binary logistic regression, and the prediction efficiency of the model was evaluated by the areas under the curve (AUC) of receiver operating characteristic (ROC). Results Among the 64 patients with myelofibrosis, DIPSS scores were 10 low risk patients, 22 intermediate risk-1 patients, 14 intermediate risk-2 patients, and 18 high risk patients; 45 cases of JAK2V617F gene mutation, 3 cases of MPL W515L/K gene mutation, 8 cases of CALR gene mutation, and 8 cases of triple negative. The results of LASSO regression showed that 13 variables were related to the efficacy of Ruxolitinib. Using MPV, BLAST, PLT and RDW-SD as predictors, the predictive model of efficacy was successfully established based on Logistic regression, with AUC of 0.774, sensitivity of 81.0% and the specificity of 69.6%. There were 23 patients (35.94%) with myelofibrosis whose spleen volume decreased by ≥35% compared with baseline; 15 patients with the initial sufficient dose of Ruxolitinib were selected strictly for subgroup analysis according to the platelet count, and the result showed that the spleen volume of 7 patients (46.67%) was reduced by ≥35% compared with the baseline, which was statistically significant compared with all patients (P<0.001). Conclusions Early treatment with sufficient dose of Ruxolitinib shows good efficacy in myelofibrosis patients, and the Logistic regression model including MPV, BLAST, PLT and RDW-SD as the predictive factors has good prediction efficacy. Related Articles | Metrics

Select

Second tumor after CAR⁃T therapy in refractory/relapsed B⁃cell tumor: Two cases study and literature review ZHANG Shiyuan, MAO Xia, HUANG Liang 2021, 13 (4):  376-379.  doi: 10.3969/j.issn.1674-5671.2021.04.08 Abstract ( 237 )   PDF (688KB) ( 182 )   Save Objective  To analyze the clinical characteristics and efficacy of chimeric antigen receptors-modified T cells (CAR-T) based therapy in the treatment of patients with refractory/relapsed B-cell tumor. Methods The data of 2 patients with B-cell tumor who developed a secondary tumor after CD19 and CD22 CAR-T therapy were retrospectively analyzed, and the related literature was reviewed. Results One case was diagnosed as follicular lymphoma and had a progression-free survival of 28 months after treatment with CD19 and CD22 CAR-T therapy, followed by secondary adenocarcinoma; the other case was diagnosed as acute B-lymphoblastic leukemia and had a progression-free survival of 14 months after CD19 CAR-T therapy, followed by secondary acute myeloid leukemia. Conclusions A great breakthrough is made in CAR-T therapy for the treatment of B-cell tumor patients. However, the therapy still has long-term adverse reactions in clinical application, such as the secondary tumor, which needs a long-term follow-up and summary in clinical practice. Related Articles | Metrics

Select

Clinical application of recombinant human thrombopoietin in patients with multiple myeloma during autologous peripheral blood stem cell transplantation YANG Guangzhong, GAO Wen, WANG Guorong, Li Yanchen, WU Yin, LIU Aijun, LENG Yun, CHEN Wenming 2021, 13 (4):  380-384.  doi: 10.3969/j.issn.1674-5671.2021.04.09 Abstract ( 203 )   PDF (479KB) ( 155 )   Save Objective  To analyze the clinical characteristics and efficacy of chimeric antigen receptors-modified T cells (CAR-T) based therapy in the treatment of patients with refractory/relapsed B-cell tumor. Methods The data of 2 patients with B-cell tumor who developed a secondary tumor after CD19 and CD22 CAR-T therapy were retrospectively analyzed, and the related literature was reviewed. Results One case was diagnosed as follicular lymphoma and had a progression-free survival of 28 months after treatment with CD19 and CD22 CAR-T therapy, followed by secondary adenocarcinoma; the other case was diagnosed as acute B-lymphoblastic leukemia and had a progression-free survival of 14 months after CD19 CAR-T therapy, followed by secondary acute myeloid leukemia. Conclusions A great breakthrough is made in CAR-T therapy for the treatment of B-cell tumor patients. However, the therapy still has long-term adverse reactions in clinical application, such as the secondary tumor, which needs a long-term follow-up and summary in clinical practice. Related Articles | Metrics

Select

Clinical efficacy of domestic bortezomib (Xintai) in the treatment  of multiple myeloma and its safety  YANG Guangzhong, GENG Chuanying, WU Yin, LIU Aijun, LENG Yun, LI Yanchen, GAO Wen, CHEN Wenming 2021, 13 (4):  385-388.  doi: 10.3969/j.issn.1674-5671.2021.04.10 Abstract ( 254 )   PDF (319KB) ( 268 )   Save Objective To evaluate the clinical efficacy and safety of domestic Bortezomib (Xintai) based regimen in the treatment of multiple myeloma. Methods Patients with multiple myeloma who received the domestic Bortezomib (Xintai) based treatment in Beijing Chao-Yang Hospital, Capital Medical University were selected as the study subjects to analyze the clinical efficacy and adverse reactions. Results A total of 117 patients with multiple myeloma were included, 80 newly diagnosed patients and 37 relapsed/refractory patients. After 4 cycles of median therapy(range 1-11 cycles), the overall response rate (ORR) was 72.6% (85/117), 91.3% (73/80) for newly diagnosed multiple myeloma and 32.4% (12/37) for relapsed/refractory multiple myeloma. The adverse reactions were mainly in grade 1-2, among which hematologic adverse reactions were mainly leukopenia and thrombocytopenia, with the incidence of 35.0% (41/117) and 32.5% (38/117), respectively; while the non-hematological adverse reactions were mainly neuropathy (32.5%, 38/117) and gastrointestinal reactions (53.0%, 62/117), respectively. Conclusions Domestic Bortezomib (Xintai) is suitable for the first-line treatment of newly diagnosed multiple myeloma patients, with good efficacy and tolerance, but the long-term efficacy require a further follow-up; the clinical efficacy of patients with relapsed and refractory multiple myeloma is poor. Related Articles | Metrics

Select

LncRNA SNHG20 regulates proliferation and invasion of cholangiocarcinoma through miR⁃520f⁃3p GUAN Canghai, LIU Lang, SHI Wujiang, WANG Jiangang, ZHONG Xiangyu, JIANG Xingming 2021, 13 (4):  389-394.  doi: 10.3969/j.issn.1674-5671.2021.04.11 Abstract ( 239 )   PDF (698KB) ( 146 )   Save  Objective  To investigate the effects of lncRNA SNHG20 and miR-520f-3p on the proliferation, migration and invasion of cholangiocarcinoma cells and the potential mechanisms. Methods The tumor tissues and corresponding adjacent tissues of 20 patients with cholangiocarcinoma who were surgically resected in the 2nd Affiliated Hospital of Harbin Medical University from March 2012 to March 2014 were collected. The si-SNHG20, miR-520f-3p mimics and miR-520f-3p inhibitor and their corresponding control plasmids were transfected into cholangiocarcinoma cells CCLP-1 by liposome transfection technology, respectively,  to construct overexpression and silence cell models. The qRT-PCR was used to detect the expression levels of SNHG20 and miR-520f-3p in cholangiocarcinoma tissues and corresponding normal tissues as well as cholangiocarcinoma cells CCLP-1, QBC939, RBE, TFK-1 and normal bile duct epithelial cells HIBEC. The cell proliferation ability was detected by CCK-8 assay. The cell migration and invasion ability were detected by wound healing and Transwell assay, respectively. The targeting relationship between SNHG20 and miR-520f-3p was verified by the dual luciferase reporter gene experiment. Results Compared with the adjacent tissues and normal bile duct epithelial cells HIBEC, the expressions of SNHG20 in CCLP-1, QBC939, RBE, TFK-1 of cholangiocarcinoma cells were significantly higher (P<0.05), while the expressions of miR-520f-3p were decreased (P<0.05). Compared with si-NC group, the proliferation, migration and invasion of CCLP-1 cells were decreased after SNHG20 knockdown (P<0.05). SNHG20 could target and regulate the expression of miR-520f-3p, and the knockdown of miR-520f-3p could reverse the inhibitory effect of down-regulated SNHG20 on the proliferation and invasion of CCLP-1 cells (t=10.533, P=0.002; t=8.683, P=0.037). Conclusions SNHG20 can target miR-520f-3p to regulate the proliferation and invasion of cholangiocarcinoma cells. Related Articles | Metrics

Select

Establishment and identification of human osteosarcoma cell line with high lung metastasis ZHI Wenlan, CHANG Junli, HU Shaopu, WANG Xiaobo, ZHAO Fulai, SUN Xingyuan, MA Xiaoping, YANG Yanping 2021, 13 (4):  394-399.  doi: 10.3969/j.issn.1674-5671.2021.04.12 Abstract ( 300 )   PDF (968KB) ( 234 )   Save Objective To establish a human osteosarcoma cell line with high lung metastasis ability and provide a research model for explore the mechanism of lung metastasis of osteosarcoma. Methods The human osteosarcoma 143B cells labeled with GFP and luciferase were resuspended into a MEM medium and mixed with Matrigel gel (1∶1) to make a cell suspension (1×107/mL) , and 10 μL of the suspension was injected into the left tibia of 4-week-old BALB/c nude mice to establish a model of lung metastasis by in situ injection into the tibia (n=6) . The lung metastasis nodules were collected to make a single-cell suspension, cultured adherently in a complete medium, and amplified with neomycin (G418) resistance screening, then inoculated into the tibia of nude mice again. The cells obtained after circulating twice in vivo by the same method were named 143B-HLM. The cell migration was detected by the vitro real-time cell migration assay, the expression of key molecular markers of cell migration and infiltration was detected by RT-qPCR and Western blot, and lung tumor nodule formation in lung metastatic tumor model was observed. Results Compared with parental human osteosarcoma 143B cells, 143B-HLM cells had higher migratory capacity in vitro; the protein expression of Vimentin and Slug, and the mRNA expression levels of Vimentin, Slug, Snail, and Survivin were increased (all P<0.05) . Compared with nude mice injected with 143B cells, the tumor-bearing model in which 143B-HLM cells were injected in situ into the tibia of nude mice, the tumor volume in situ was decreased (P<0.05), the fluorescence intensity of lung tumor metastasis was significantly increased, and the number of lung metastasis was also increased (P<0.01). Conclusions A stable osteosarcoma cell line 143B-HLM with high lung metastatic capacity was successfully established through in vivo circulation screening and isolation of osteosarcoma metastatic cells. Related Articles | Metrics

Select

Regulation of the malignant biological behavior of nasopharyngeal carcinoma cells by lncRNA PRNCR1 targeting miR⁃653⁃5p ZHAO Liyang, CUI Ling, ZHANG Ying, WANG Ling, LI Huizheng 2021, 13 (4):  400-406.  doi: 10.3969/j.issn.1674-5671.2021.04.13 Abstract ( 225 )   PDF (1077KB) ( 117 )   Save Objective To investigate the effect of long non-coding RNA(lncRNA) PRNCR1 on the malignant biological behavior of nasopharyngeal carcinoma cells and its possible mechanism. Methods The expressions of PRNCR1 and miR-653-5p in the Nasopharyngeal carcinoma cell lines(5-8F, 6-10B, C666-1) and nasopharyngeal epithelial cells NP69 were detected by RT-qPCR.  The si-PRNCR1 and miR-653-5p mimics or co-transfected with si-PRNCR1 and anti-miR-653-5p, were transfected into nasopharyngeal carcinoma 6-10B cells，respectively. The cell proliferation was detected by CCK-8 method, cell apoptosis was detected by flow cytometry, cell migration was detected by scratch test, cell invasion was detected by Transwell chamber test, and the targeting relationship between PRNCR1 and miR-653-5p was verified by the dual luciferase reporter gene experiment. Results The expression level of PRNCR1 in nasopharyngeal carcinoma cell lines (5-8F, 6-10B, C666-1) was higher than that of nasopharyngeal epithelial cells NP69 (all P<0.001), while the expression level of miR-653-5p was lower than that of NP69 cells(all P<0.001). After knocking down PRNCR1 or overexpressing miR-653-5p, the proliferation ability, scratch healing rate and invasion number of nasopharyngeal carcinoma 6-10B cells were decreased (all P<0.001), but the apoptosis rate was increased (all P<0.001). The dual luciferase reporter assay confirmed that PRNCR1 had a targeting relationship with miR-653-5p. After knocking down PRNCR1, the expression level of miR-653-5p in 6-10B cells was increased (P<0.001). Knocking down miR-653-5p could reverse the effect of knocking down PRNCR1 on the proliferation, apoptosis, migration and invasion of nasopharyngeal carcinoma 6-10B cells. Conclusions PRNCR1 is highly expressed in nasopharyngeal carcinoma cell lines. The knockdown of PRNCR1 expression can inhibit the proliferation, migration and invasion of nasopharyngeal carcinoma cells, and promote cells apoptosis. The underlying mechanism may be related to the targeted negative regulation of miR-653-5p. Related Articles | Metrics

Select

A real⁃world study of the efficacy and safety of Palbociclib combined with endocrine therapy for advanced hormone receptor⁃positive breast cancer XU Junnan, CAO Hui, JIANG Yujun, LI Huan, DONG Fangyuan, DUAN Yangyang, JING Mingxi, GUO Xiangyu, SUN Tao 2021, 13 (4):  406-412.  doi: 10.3969/j.issn.1674-5671.2021.04.14 Abstract ( 252 )   PDF (770KB) ( 213 )   Save Objective To evaluate the efficacy and safety of Palbociclib combined with endocrine therapy for HR+ /HER2- advanced breast cancer (ABC). Methods The clinical data of 83 patients with HR+ /HER2- ABC in our center from September 15, 2018 to October 30, 2020 were retrospectively analyzed to evaluate the clinical efficacy, progression-free survival (PFS) and adverse effects of Palbociclib combined with endocrine therapy. Results A total of 83 patients with HR+ /HER2- ABC were enrolled and the median follow-up time was 15.5 months. The ORR of the first-line patients (n=25) and the second-line patients (n=38) received Palbociclib combined with endocrine therapy were higher than those of the multi-line patients (n=20), but the difference was not statistically significant (48.0% vs 44.7% vs 30.0%, P=0.466), and there was no statistically significant difference in DCR among the three groups (96.0% vs 89.5% vs 80.0%, P=0.337). The median progression-free survival (mPFS) in the Palbociclib combined group was 13.0 months (95%CI: 11.4 to 14.6 months), the first-line/the second-line patients had longer mPFS than the multi-line patients (20.0 months vs 14.0 months vs 5.0 months, P<0.001), and only the bone metastases patients had better mPFS than patients without bone metastases (NR months vs 13.0 months; HR=0.42, 95%CI: 0.22-0.84, P=0.01); mPFS in patients without visceral metastasis was better than those with visceral metastasis, but the difference was not statistically significant (20.0 months  vs 13.0 months; HR=0.65, 95%CI: 0.35-1.22, P=0.38). Patients who were resistant to Everolimus combined with endocrine therapy still benefited from Palbociclib (mPFS=5 months). The most common and serious adverse effects of 83 patients received Palbociclib combined were neutropenia, among which 12 patients were dose-reduced due to adverse effects. Conclusions Palbociclib combined with endocrine therapy for HR+ /HER2- ABC patients has a significant clinical efficacy and good safety, especially the first-line /the second-line treatment has achienved good efficacy. Related Articles | Metrics

Select

韦滔,唐置鸿,韦猛,林有智,陈洁,白涛,王小波,齐鲁楠,唐娟,黎乐群,吴飞翔 WEI Tao, TANG Zhihong, WEI Meng, LIN Youzhi, CHEN Jie, BAI Tao, WANG Xiaobo, QI Lunan, TANG Juan, LI 2021, 13 (4):  413-419.  doi: 10.3969/j.issn.1674-5671.2021.04.15 Abstract ( 422 )   PDF (816KB) ( 199 )   Save Objective To investigate the effect of transcatheter arterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKI) and programmed death-1 (PD-1) inhibitors in the conversion therapy for patients with unresectable hepatocellular carcinoma. Methods Clinical data of 22 patients  with unresectable hepatocellular carcinoma receiving TACE combined with TKI and PD-1 inhibitors were collected and analyzed in the hepatocellular carcinoma ward of Guangxi Medical University Cancer Hospital from November 2019 to December 2020. The primary research endpoint was surgical conversion rate, and the secondary research endpoints were tumor response, objective response rate, disease control rate, progression-free survival, overall survival and poor response. Results Among 22 patients, the surgical conversion rate was 45.5% (10/22), the objective remission rate was 81.8% (18/22), and the disease control rate was 90.9% (20/22). The median progression-free survival and the median overall survival did not reach the observation endpoint. The incidence of treatment-related adverse reactions (TRAE) was 100% (22/22), and the incidence of ≥3 grade TRAE was 59% (13/22). Among the 10 patients with successful conversion therapy, the median time from treatment to surgery was 4.7 months (IQR: 3.4-8.4 months), the median operation time was 271 min (IQR: 210-313 min), the median blood loss was 225 mL (IQR: 100-425 mL), the postoperative median drainage tube extubation time was 6.0 d (IQR: 4.8-8.5 d), and the median postoperative hospital stay was 10.0 d( IQR: 8.5-12.3 d); 3 cases had complete remission; the median follow-up time after operation was 3.5 months, and no tumor recurrence or death was found. Conclusions TACE combined with TKI and PD-1 inhibitors may be an effective and safe conversion therapy strategy for unresectable hepatocellular carcinoma. Related Articles | Metrics

Select

Expression of KIF20A in T1 high⁃grade bladder cancer and its value in predicting postoperative recurrence REN Weigang, LI Jiahui, LI Tieqiu, TAN Wubin, ZHOU Song 2021, 13 (4):  420-424.  doi: 10.3969/j.issn.1674-5671.2021.04.16 Abstract ( 185 )   PDF (679KB) ( 161 )   Save  Objective To investigate the expression of kinesin family member 20A (KIF20A) in T1 high-grade (T1HG) bladder cancer tissues and its value in predicting postoperative recurrence. Methods A total of  94 tumor tissues and matched adjacent tissues (≥3 cm from the edge of the tumor) were selected from patients who underwent the first transurethral resection of bladder cancer in the department of urology of our hospital from August 2013 to December 2015, and the postoperative pathological diagnosis was T1HG bladder cancer. The expression of KIF20A protein was detected by immunohistochemistry. The recurrence of the tumor was monitored by cystoscopy, and the value of KIF20A protein expression in predicting postoperative recurrence was analyzed by Cox proportional hazard regression analysis. Results The TCGA database analysis showed that the expression of KIF20A mRNA in bladder cancer tissues was higher than that in normal tissues (P<0.05). Moreover, the disease-free progression rate of patients with bladder cancer in the high expression group of KIF20A was significantly lower than that in the low expression group (P=0.012). The analysis of clinical samples showed that the positive rate of KIF20A protein in T1HG bladder cancer tissues was significantly higher than that in adjacent tissues (12.8% vs 64.9%, P<0.001), and the expression level of KIF20A protein was correlated with age, smoking history, tumor diameter, T1 sub-stage and pathological grade (all P<0.05). Patients with KIF20A protein positive expression had shorter recurrence free survival than those with negative expression(log-rank χ2=16.154, P<0.001). The multivariable Cox proportional hazard regression analysis showed that the positive expression of KIF20A protein was an independent risk factor for postoperative recurrence (OR=3.033, 95%CI:1.451-6.339, P=0.003). Conclusions The KIF20A protein is highly expressed in T1HG bladder cancer tissues, and expected to be an effective biological indicator to predict the postoperative recurrence risk of T1HG bladder cancer. Related Articles | Metrics

Select

Research progress on accelerating partial breast irradiation WANG Zimeng, XIANG Zuolin 2021, 13 (4):  425-429.  doi: 10.3969/j.issn.1674-5671.2021.04.17 Abstract ( 353 )   PDF (338KB) ( 410 )   Save Related Articles | Metrics

Select

m6A modification of non⁃coding RNA and its research progress in tumors HU Binbin, ZHANG Ming 2021, 13 (4):  430-435.  doi: 10.3969/j.issn.1674-5671.2021.04.18 Abstract ( 273 )   PDF (460KB) ( 439 )   Save Related Articles | Metrics

Select

Research progress of hyperthermic intraperitoneal chemotherapy for gynecological malignant tumors SHAO Ruyu, YAO Desheng 2021, 13 (4):  436-441.  doi: 10.3969/j.issn.1674-5671.2021.04.19 Abstract ( 271 )   PDF (389KB) ( 257 )   Save Related Articles | Metrics

Select

Research progress of sarcopenia in patients with gastric cancer JIA Kui, CHEN Junqiang, TANG Mengjuan 2021, 13 (4):  441-446.  doi: 10.3969/j.issn.1674-5671.2021.04.20 Abstract ( 223 )   PDF (348KB) ( 230 )   Save Related Articles | Metrics